Related Experiment Video
Updated: Mar 21, 2026
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise
Abstract:
Metastatic prostate cancer remains a highly lethal disease with no curative therapeutic options. A significant subset of patients with prostate cancer harbor either germline or somatic mutations in DNA repair enzyme genes such as BRCA1, BRCA2, or ATM. Emerging data suggest that drugs that target poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) enzymes may represent a novel and effective means of treating tumors with these DNA repair defects, including prostate cancers. Here we will review the molecular mechanism of action of PARP inhibitors and discuss how they target tumor cells with faulty DNA repair functions and transcriptional controls. We will review emerging data for the utility of PARP inhibition in the management of metastatic prostate cancer. Finally, we will place PARP inhibitors within the framework of precision medicine-based care of patients with prostate cancer.
Insights
PARP inhibitors offer a promising new treatment for metastatic prostate cancer by targeting DNA repair defects. These drugs are key to precision medicine for patients with specific genetic mutations.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Metastatic prostate cancer is a lethal disease with limited treatment options.
- A subset of patients have DNA repair gene mutations (e.g., BRCA1, BRCA2, ATM).
Purpose of the Study:
- To review the mechanism of action of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors.
- To discuss the utility of PARP inhibitors in treating metastatic prostate cancer with DNA repair defects.
- To position PARP inhibitors within precision medicine for prostate cancer care.
Main Methods:
- Review of molecular mechanisms of PARP inhibitors.
- Analysis of emerging clinical data on PARP inhibition in prostate cancer.
- Discussion of targeting DNA repair defects and transcriptional controls.
Main Results:
- PARP inhibitors exploit synthetic lethality in tumors with DNA repair deficiencies.
- Emerging data show potential efficacy of PARP inhibitors in metastatic prostate cancer.
- PARP inhibitors represent a precision medicine approach.
Conclusions:
- PARP inhibitors are a novel therapeutic strategy for a subset of prostate cancer patients.
- Targeting DNA repair defects with PARP inhibitors aligns with precision medicine principles.
- Further research is warranted to optimize PARP inhibitor use in prostate cancer management.
